General Information
Arisaph Lipids ARI-3037MO-005
REASCEND: Randomized Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia.
| Protocol | ARI-3037MO-005 |
|---|---|
| Identifier | Site No: 012 |
| UID | 92827687-30b7-4ccb-b40d-c83bd97b8036 |
| Status | Done - Archived |
| Phase | 2a |
| Category | High Cholesterol / Adult |
| Launch Year | 2015 |
| NCT Number | - |
| Created | 2015-06-23 11:38 |
| Last Updated | 2015-06-23 11:38 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | No | |
| Enrollment Open | No | |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2015-08-20 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2016-08-30 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Martinez, Gilbert | GJMartinez | No |
| Recruiter | - | No | |
| Coordinator | Valenzuela, Louisito | LValenzuela | No |
| Regulatory | Aguirre, Sandra | SAguirre | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Arisaph Pharmaceuticals |
|---|---|
| Division | Arisaph Pharmaceuticals |
| Team | Arisaph Pharmaceuticals |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | Medpace, Inc. |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
